165 results on '"Dawson GR"'
Search Results
2. Agomelatine facilitates positive emotional processing in healthy volunteers
- Author
-
Goodwin, GM, de Bodinat, C, Dawson, GR, Dourish, CT, Waldenmaier, L, Adams, S, Cowen, PJ, and Harmer, CJ
- Published
- 2016
3. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy
- Author
-
Schmechtig, A, primary, Lees, J, additional, Dawson, GR, additional, Dourish, CT, additional, Craig, KJ, additional, Deakin, JFW, additional, Wilkinson, L, additional, Williams, SCR, additional, and Ettinger, U, additional
- Published
- 2011
- Full Text
- View/download PDF
4. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist
- Author
-
Atack, JR, primary, Hallett, DJ, additional, Tye, S, additional, Wafford, KA, additional, Ryan, C, additional, Sanabria-Bohórquez, SM, additional, Eng, Wai-si, additional, Gibson, RE, additional, Burns, HD, additional, Dawson, GR, additional, Carling, RW, additional, Street, LJ, additional, Pike, A, additional, De Lepeleire, I, additional, Van Laere, K, additional, Bormans, G, additional, de Hoon, JN, additional, Van Hecken, A, additional, McKernan, RM, additional, Murphy, MG, additional, and Hargreaves, RJ, additional
- Published
- 2010
- Full Text
- View/download PDF
5. MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans
- Author
-
Atack, JR, primary, Wafford, KA, additional, Street, LJ, additional, Dawson, GR, additional, Tye, S, additional, Van Laere, K, additional, Bormans, G, additional, Sanabria-Bohórquez, SM, additional, De Lepeleire, I, additional, de Hoon, JN, additional, Van Hecken, A, additional, Burns, HD, additional, McKernan, RM, additional, Murphy, MG, additional, and Hargreaves, RJ, additional
- Published
- 2010
- Full Text
- View/download PDF
6. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women
- Author
-
Halford, JCG, primary, Boyland, EJ, additional, Cooper, SJ, additional, Dovey, TM, additional, Huda, MSB, additional, Dourish, CT, additional, Dawson, GR, additional, and Wilding, JPH, additional
- Published
- 2008
- Full Text
- View/download PDF
7. Observing Change Over Time in Strength-Based Parenting and Subjective Wellbeing for Pre-teens and Teens
- Author
-
Lea Waters, Daniel J. Loton, Dawson Grace, Rowan Jacques-Hamilton, and Michael J. Zyphur
- Subjects
wellbeing ,parenting ,strengths ,adolescence ,pre-teens ,teens ,Psychology ,BF1-990 - Abstract
The focus of this study was on adolescent mental health. More specifically, the relationship between strength-based parenting (SBP) and subjective wellbeing (SWB) during adolescence was examined at three time points over 14 months (N = 202, Mage = 12.97, SDage = 0.91, 48% female). SBP was positively related to life satisfaction and positive affect at each of the three time points, and was negatively related to negative affect. SBP and SWB both declined significantly over time. When examining the causal relationships between SBP and SWB, two different statistical models were applied: latent growth-curve models (LGM) and random-intercept cross-lagged panel models (RI-CLPM). The LGM revealed a strong positive relationship between changes in SBP and SWB. Specifically, this model showed that SBP at one time point predicted adolescent SWB at future time points. However, when the more stringent statistical test was completed through RI-CLPMs, no cross-lagged paths reached significance. Thus, while parenting is a significant predictor of wellbeing for pre-teens and teens in real time, it is not predictive of wellbeing at future time points. Parents, thus, cannot assume that their current levels of SBP are ‘banked’ by their children to support future wellbeing. Instead, SBP needs to be an ongoing, contemporary parenting practice. Furthermore, the fact that perceptions of SBP decline in this age bracket suggest that SBP interventions may be helpful in supporting adolescent mental health.
- Published
- 2019
- Full Text
- View/download PDF
8. Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)
- Author
-
Bailey JE, Dawson GR, Dourish CT, and Nutt DJ
- Published
- 2011
9. Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety.
- Author
-
Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, Dourish CT, Dawson GR, and Nutt DJ
- Published
- 2011
10. Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze.
- Author
-
Antonova E, Parslow D, Brammer M, Simmons A, Williams S, Dawson GR, and Morris R
- Published
- 2011
11. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.
- Author
-
Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Bohórquez SM, Eng WS, Gibson RE, Burns HD, Dawson GR, Carling RW, Street LJ, Pike A, De Lepeleire I, Van Laere K, Bormans G, de Hoon JN, Van Hecken A, McKernan RM, and Murphy MG
- Abstract
In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABA(A) receptor occupancy (∼10%). Since it was not clear whether this sedation was mediated via the α2/α3 or α1 GABA(A) subtype(s), we characterized the properties of TPA023B, a high-affinity imidazotriazine which, like MRK-409, has partial agonist efficacy at the α2 and α3 subtype but is an antagonist at the α1 subtype, at which MRK-409 has weak partial agonism. TPA023B gave dose- and time-dependent occupancy of rat brain GABA(A) receptors as measured using an in vivo [(3)H]flumazenil binding assay, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL, the latter of which was similar to that observed in mice (25 ng/mL) and comparable to values obtained in baboon and man using [(11)C]flumazenil PET (10 and 5.8 ng/mL, respectively). TPA023B was anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle, conditioned suppression of drinking, conditioned emotional response) yet had no significant effects in rodent or primate assays of ataxia and/or myorelaxation (rotarod, chain-pulling, lever pressing), up to doses (10 mg/kg) corresponding to occupancy of greater than 99%. In man, TPA023B was well tolerated at a dose (1.5 mg) that produced occupancy of >50%, suggesting that the sedation previously seen with MRK-409 is due to the partial agonist efficacy of that compound at the α1 subtype, and highlighting the importance of antagonist efficacy at this particular GABA(A) receptor population for avoiding sedation in man. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
12. Special issue on CNS experimental medicine.
- Author
-
Dawson GR, Dourish CT, and Goodwin GM
- Published
- 2011
13. Trace element mobility during CO2 storage: application of reactive transport modelling
- Author
-
Kirste Dirk, Pearce Julie K., Golding Sue D., and Dawson Grant K.W.
- Subjects
Environmental sciences ,GE1-350 - Abstract
The geologic storage of CO2 carries both physical and chemical risks to the environment. In order to reduce those risks, it is necessary to provide predictive capabilities for impacts so that strategies can be developed to monitor, identify and mitigate potential problems. One area of concern is related to water quality both in the reservoir and in overlying aquifers. In this study we report the critical steps required to develop chemically constrained reactive transport models (RTM) that can be used to address risk assessment associated with water quality. The data required to produce the RTM includes identifying the individual hydrostratigraphic units and defining the mineral and chemical composition to sufficient detail for the modelling. This includes detailed mineralogy, bulk chemical composition, reactive mineral phase chemical composition and the identification of the occurrence and mechanisms of mobilisation of any trace elements of interest. Once the required detail is achieved the next step involves conducting experiments to determine the evolution of water chemistry as reaction proceeds preferably under varying elevated CO2 fugacities with and without impurities. Geochemical modelling of the experiments is then used for characterising the reaction pathways of the different hydrostratigraphic units. The resultant geochemical model inputs can then be used to develop the chemical components of a reactive transport model.
- Published
- 2019
- Full Text
- View/download PDF
14. Clinical orthpaedic tips
- Author
-
Dawson Gr
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Medical physics ,General Medicine ,business - Published
- 1971
15. 'NO TRUCE FOR TUBERCULOSIS'
- Author
-
Dawson Gr
- Subjects
Tuberculosis ,business.industry ,medicine ,General Medicine ,medicine.disease ,business ,Virology - Published
- 1964
16. Policy Analytics, Household Informedness and the Collection of Household Hazardous Waste
- Author
-
Lim-Wavde Kustini, Kauffman Robert J., and Dawson Gregory S.
- Subjects
Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
Proper collection of Household Hazardous Waste (HHW) is an important action to support environmental sustainability. We investigate the role of household informedness, the degree to which households have the necessary information to make utility-maximizing decisions, as they relate to participation in HHW collection programs. We find two factors that influence household informedness: the provision of public education about HHW and environmental quality information. We conducted an empirical study on HHW collection in California to obtain statistical evidence on the effect of these factors on the amount of HHW collected. The findings of this policy analytics study improve our understanding of how household informedness influences household decision-making in participating in HHW collection programs. This study is useful in the guidance it offers to devise new information policies to maximize households’ participation in HHW collection program.
- Published
- 2016
- Full Text
- View/download PDF
17. The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide.
- Author
-
Umbricht D, Kas MJH, and Dawson GR
- Abstract
The failure rate of drugs being developed for neuropsychiatric indications remains high. Optimizing drug discovery and development requires not only a better neurobiological understanding of disease aetiology and development, but also the means by which we can measure relevant biological and clinical processes related to disease progression, drug target engagement, and sensitivity to treatment. Here we address the role and key considerations for the selection of biomarkers in clinical drug development for neuropsychiatric disorders. We do not provide an exhaustive list of biomarkers; rather we lay out a pragmatic, well-defined biomarker selection strategy that addresses the main goals for each of the phases in the drug development cycle. We discuss the key questions and issues that concern biomarker selection and implementation in each phase of development. For the better development of biomarkers, we emphasize the need to focus on discrete biological dysfunction and/or symptom domains rather than diagnoses. We also advocate the use of biomarker-based patient stratification in phase 2 and 3 to increase sensitivity and power and reduce costs. Our aim is to enhance precision and chances of success for these complex and heterogeneous brain disorders with a high unmet medical need., Competing Interests: Conflicts of interests DU is owner of xperimed LLC that provides consultation on all aspects of clinical drug development for neuropsychiatric indications, works on a contracting basis for Autifony Therapeutics and Gilgamesh pharmaceuticals and holds stocks of Roche, Novartis and Gilgamesh Pharmaceuticals. He has been consulting to Abbvie, Biogen, ERG, Forbion, Healthrhyhms, Kynexis, Psychogenic, Roche and Siesta. MJHK declares no conflicts of interest. GRD is owner of P1vital LTD that provides consultation on suitable biomarkers for inclusion in clinical clinicals and supplies biomarkers such as the Facial expression recognition task (FERT, described in the text to industry and academia., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Social dysfunction relates to shifts within socioaffective brain systems among Schizophrenia and Alzheimer's disease patients.
- Author
-
Braak S, Penninx BW, Su T, Pijnenburg Y, Nijland D, Campos AV, de la Torre-Luque A, Saris IMJ, Reus LM, Beckenstrom AC, Malik A, Dawson GR, Marston H, Alvarez-Linera J, Ayuso-Mateos JL, Arango C, van der Wee N, Kas MJ, and Aghajani M
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Schizophrenic Psychology, Social Behavior, Brain Mapping methods, Alzheimer Disease physiopathology, Alzheimer Disease psychology, Alzheimer Disease diagnostic imaging, Magnetic Resonance Imaging, Brain physiopathology, Brain diagnostic imaging, Schizophrenia physiopathology, Schizophrenia diagnostic imaging, Emotions physiology
- Abstract
Social dysfunction represents one of the most common signs of neuropsychiatric disorders, such as Schizophrenia (SZ) and Alzheimer's disease (AD). Perturbed socioaffective neural processing is crucially implicated in SZ/AD and generally linked to social dysfunction. Yet, transdiagnostic properties of social dysfunction and its neurobiological underpinnings remain unknown. As part of the European PRISM project, we examined whether social dysfunction maps onto shifts within socioaffective brain systems across SZ and AD patients. We probed coupling of social dysfunction with socioaffective neural processing, as indexed by an implicit facial emotional processing fMRI task, across SZ (N = 46), AD (N = 40) and two age-matched healthy control (HC) groups (N = 26 HC-younger and N = 27 HC-older). Behavioural (i.e., social withdrawal, interpersonal dysfunction, diminished prosocial or recreational activity) and subjective (i.e., feelings of loneliness) aspects of social dysfunction were assessed using the Social Functioning Scale and De Jong-Gierveld loneliness questionnaire, respectively. Across SZ/AD/HC participants, more severe behavioural social dysfunction related to hyperactivity within fronto-parieto-limbic brain systems in response to sad emotions (P = 0.0078), along with hypoactivity of these brain systems in response to happy emotions (P = 0.0418). Such relationships were not found for subjective experiences of social dysfunction. These effects were independent of diagnosis, and not confounded by clinical and sociodemographic factors. In conclusion, behavioural aspects of social dysfunction across SZ/AD/HC participants are associated with shifts within fronto-parieto-limbic brain systems. These findings pinpoint altered socioaffective neural processing as a putative marker for social dysfunction, and could aid personalized care initiatives grounded in social behaviour., Competing Interests: Declaration of competing interest Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. AM and GRD are full-time employees of P1vital Ltd. GRD is an owner and shareholder of P1vital Ltd. and P1vital Products Ltd. ACB is an employee of P1vital Products Ltd. All other authors declare that they have nothing to disclose., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. When a test is more than just a test: Findings from patient interviews and survey in the trial of a technology to measure antidepressant medication response (the PReDicT Trial).
- Author
-
Brown S, Ploeger C, Guo B, Petersen JJ, Beckenstrom AC, Browning M, Dawson GR, Deckert J, Dias R, Dourish CT, Gorwood P, Kingslake J, Menke A, Sola VP, Reif A, Ruhe H, Simon J, Stäblein M, van Schaik A, Veltman DJ, and Morriss R
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Surveys and Questionnaires, Depression drug therapy, Depression psychology, Depression diagnosis, Aged, Germany, Europe, Qualitative Research, Antidepressive Agents therapeutic use
- Abstract
Background: A RCT of a novel intervention to detect antidepressant medication response (the PReDicT Test) took place in five European countries, accompanied by a nested study of its acceptability and implementation presented here. The RCT results indicated no effect of the intervention on depression at 8 weeks (primary outcome), although effects on anxiety at 8 weeks and functioning at 24 weeks were found., Methods: The nested study used mixed methods. The aim was to explore patient experiences of the Test including acceptability and implementation, to inform its use within care. A bespoke survey was completed by trial participants in five countries (n = 778) at week 8. Semi-structured interviews were carried out in two countries soon after week 8 (UK n = 22, Germany n = 20). Quantitative data was analysed descriptively; for qualitative data, thematic analysis was carried out using a framework approach. Results of the two datasets were interrogated together., Outcomes: Survey results showed the intervention was well received, with a majority of participants indicating they would use it again, and it gave them helpful extra information; a small minority indicated the Test made them feel worse. Qualitative data showed the Test had unexpected properties, including: instigating a process of reflection, giving participants feedback on progress and new understanding about their illness, and making participants feel supported and more engaged in treatment., Interpretation: The qualitative and quantitative results are generally consistent. The Test's unexpected properties may explain why the RCT showed little effect, as properties were experienced across both trial arms. Beyond the RCT, the qualitative data sheds light on measurement reactivity, i.e., how measurements of depression can impact patients., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Exploring the incidence of inadequate response to antidepressants in the primary care of depression.
- Author
-
Abrahams AB, Beckenstrom AC, Browning M, Dias R, Goodwin GM, Gorwood P, Kingslake J, Morriss R, Reif A, Ruhé HG, Simon J, and Dawson GR
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Quality of Life, Incidence, Depression drug therapy, Depression epidemiology, Aged, United Kingdom epidemiology, Depressive Disorder, Treatment-Resistant drug therapy, Depressive Disorder, Treatment-Resistant epidemiology, Treatment Outcome, Antidepressive Agents therapeutic use, Primary Health Care
- Abstract
Data from the UK suggests 13-55 % of depression patients experience some level of treatment resistance. However, little is known about how physicians manage inadequate response to antidepressants in primary care. This study aimed to explore the incidence of inadequate response to antidepressants in UK primary care. One-hundred-eighty-four medication-free patients with low mood initiated antidepressant treatment and monitored severity of depression symptoms, using the QIDS-SR16, for 48 weeks. Medication changes, visits to healthcare providers, and health-related quality of life were also recorded. Patients were classified into one of four response types based on their QIDS scores at three study timepoints: persistent inadequate responders (<50 % reduction in baseline QIDS at all timepoints), successful responders (≥50 % reduction in baseline QIDS at all timepoints), slow responders (≥50 % reduction in QIDS at week 48, despite earlier inadequate responses), and relapse (initial ≥50 % reduction in baseline QIDS, but inadequate response by week 48). Forty-eight weeks after initiating treatment 47 % of patients continued to experience symptoms of depression (QIDS >5), and 20 % of patients had a persistent inadequate response. Regardless of treatment response, 96 % (n = 176) of patients did not visit their primary care physician over the 40-week follow-up period. These results suggest that despite receiving treatment, a considerable proportion of patients with low mood remain unwell and fail to recover. Monitoring depression symptoms remotely can enable physicians to identify inadequate responders, allowing patients to be reassessed or referred to secondary services, likely improving patients' quality of life and reducing the socioeconomic impacts of chronic mental illness., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GRD and JK own shares in the study sponsor (P1vital Products Ltd) which also owns the PReDicT predictive algorithm. ACB, RD, and JK are employees of P1vital Products Ltd. GRD owns shares in P1vital Ltd. ABA and GRD are employees of P1vital Ltd. HGR reports speakers’ bureau honoraria from Janssen, Lundbeck, and received research grants from ZonMW, HersenStichting, EU Horizon 2020, the Dutch Ministry of Health, and an unrestricted Educational grant from Janssen. AR has received honoraria for lectures and/or advisory boards from Janssen, Boehringer Ingelheim, COMPASS, SAGE/Biogen, LivaNova, Medice, Shire/Takeda and cyclerion. Also, he has received research grants from Medice and Janssen. GMG is Chief Medical Officer at Compass pathways, holds shares and options in Compass pathways and has served as consultant, advisor or CME speaker in the last 3 years for Beckley Psytech, Boehringer Ingelheim, Clerkenwell Health, Compass pathways, Evapharma, Janssen, Lundbeck, Medscape, Novartis, Ocean Neuroscience, P1Vital Ltd., Sage, Servier and Takeda. MB has acted as a consultant for Janssen Research, P1vital Ltd, Boehringer and CHDR, and was previously a paid employee of P1vital Ltd. RM has received payment from Novartis plc but have no other conflicts of interest to report. All other authors declare that they have no conflicts of interest. JS has received research grants from the ECNP, EU Horizon 2020, EU Horizon Europe, FWF, NIHR, WWTF, and academic advisor honoraria from the European Brain Council, (Copyright © 2024 Elsevier B.V. and ECNP. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients.
- Author
-
Kas MJH, Jongs N, Mennes M, Penninx BWJH, Arango C, van der Wee N, Winter-van Rossum I, Ayuso-Mateos JL, Bilderbeck AC, l'Hostis P, Beckmann CF, Dawson GR, Sommer B, and Marston HM
- Subjects
- Humans, Schizophrenia diagnosis, Alzheimer Disease diagnosis
- Abstract
The current neuropsychiatric nosological categories underlie pragmatic treatment choice, regulation and clinical research but does not encompass biological rationale. However, subgroups of patients suffering from schizophrenia or Alzheimer's disease have more in common than the neuropsychiatric nature of their condition, such as the expression of social dysfunction. The PRISM project presents here initial quantitative biological insights allowing the first steps toward a novel trans-diagnostic classification of psychiatric and neurological symptomatology intended to reinvigorate drug discovery in this area. In this study, we applied spectral clustering on digital behavioural endpoints derived from passive smartphone monitoring data in a subgroup of Schizophrenia and Alzheimer's disease patients, as well as age matched healthy controls, as part of the PRISM clinical study. This analysis provided an objective social functioning characterization with three differential clusters that transcended initial diagnostic classification and was shown to be linked to quantitative neurobiological parameters assessed. This emerging quantitative framework will both offer new ways to classify individuals in biologically homogenous clusters irrespective of their initial diagnosis, and also offer insights into the pathophysiological mechanisms underlying these clusters., Competing Interests: Conflict of interest MK has received (non-related) research funding from Novartis during the conduct of the study. MM is employee and CFB is director and shareholder of SBGneuro Ltd. CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. BP has received (non-related) research funding from Jansen Research and Boehringer Ingelheim during the conduct of the study. ACB and GRD were fully employed by P1Vital during the conduct of the study. BS was fully employed by Boehringer Ingelheim during the conduct of the study. HM was fully employed by Eli Lilly and Company during the conduct of the study. All other authors declare no conflict of interests., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
22. Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
- Author
-
Perini F, Nazimek JM, Mckie S, Capitão LP, Scaife J, Pal D, Browning M, Dawson GR, Nishikawa H, Campbell U, Hopkins SC, Loebel A, Elliott R, Harmer CJ, Deakin B, and Koblan KS
- Abstract
Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist without antagonist activity at dopamine D
2 or the serotonin 5-HT2A receptors, has demonstrated efficacy in the treatment of schizophrenia. Here we report the phase 1 translational studies that profiled the effect of ulotaront on brain responses to reward, working memory, and resting state connectivity (RSC) in individuals with low or high schizotypy (LS or HS). Participants were randomized to placebo (n = 32), ulotaront (50 mg; n = 30), or the D2 receptor antagonist amisulpride (400 mg; n = 34) 2 h prior to functional magnetic resonance imaging (fMRI) of blood oxygen level-dependent (BOLD) responses to task performance. Ulotaront increased subjective drowsiness, but reaction times were impaired by less than 10% and did not correlate with BOLD responses. In the Monetary Incentive Delay task (reward processing), ulotaront significantly modulated striatal responses to incentive cues, induced medial orbitofrontal responses, and prevented insula activation seen in HS subjects. In the N-Back working memory task, ulotaront modulated BOLD signals in brain regions associated with cognitive impairment in schizophrenia. Ulotaront did not show antidepressant-like biases in an emotion processing task. HS had significantly reduced connectivity in default, salience, and executive networks compared to LS participants and both drugs reduced this difference. Although performance impairment may have weakened or contributed to the fMRI findings, the profile of ulotaront on BOLD activations elicited by reward, memory, and resting state is compatible with an indirect modulation of dopaminergic function as indicated by preclinical studies. This phase 1 study supported the subsequent clinical proof of concept trial in people with schizophrenia.Clinical trial registration: Registry# and URL: ClinicalTrials.gov NCT01972711, https://clinicaltrials.gov/ct2/show/NCT01972711., (© 2023. Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
23. Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation.
- Author
-
Beckenstrom AC, Coloma PM, Dawson GR, Finlayson AK, Malik A, Post A, Steiner MA, and Potenza MN
- Subjects
- Animals, Humans, Orexin Receptors, Orexins, Mental Disorders drug therapy, Neuropeptides, Biomedical Research
- Abstract
Despite progress in understanding the pathological mechanisms underlying psychiatric disorders, translation from animal models into clinical use remains a significant bottleneck. Preclinical studies have implicated the orexin neuropeptide system as a potential target for psychiatric disorders through its role in regulating emotional, cognitive, and behavioral processes. Clinical studies are investigating orexin modulation in addiction and mood disorders. Here we review performance-outcome measures (POMs) arising from experimental medicine research methods which may show promise as markers of efficacy of orexin receptor modulators in humans. POMs provide objective measures of brain function, complementing patient-reported or clinician-observed symptom evaluation, and aid the translation from preclinical to clinical research. Significant challenges include the development, validation, and operationalization of these measures. We suggest that collaborative networks comprising clinical practitioners, academics, individuals working in the pharmaceutical industry, drug regulators, patients, patient advocacy groups, and other relevant stakeholders may provide infrastructure to facilitate validation of experimental medicine approaches in translational research and in the implementation of these approaches in real-world clinical practice., Competing Interests: Declaration of interest Amy C. Beckenstrom: Part-time employee of P1vital Ltd. Preciosa M. Coloma: Full-time employee of, and owns shares at, Idorsia Pharmaceuticals Ltd. Gerard R. Dawson: Full-time employee of P1vital Ltd. Ailidh K. Finlayson: Part-time employee of P1vital Ltd. Asad Malik: Full-time employee of P1vital Ltd. Anke Post: None. Michel Alexander Steiner: Full-time employee of, and owns shares at, Idorsia Pharmaceuticals Ltd. Marc N. Potenza: Dr. Potenza has consulted for Opiant Therapeutics, Game Day Data, Baria-Tek, the Addiction Policy Forum, AXA and Idorsia Pharmaceuticals; has been involved in a patent application with Yale University and Novartis; has received research support from Mohegan Sun Casino and the Connecticut Council on Problem Gambling; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse-control disorders or other health topics; has consulted for and/or advised gambling and legal entities on issues related to impulsive, compulsive and addictive disorders; has edited journals and journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. Conflict of interest statement Dr. Potenza discloses the following. Dr. Potenza has consulted for Opiant Therapeutics, Game Day Data, Baria-Tek, the Addiction Policy Forum, AXA and Idorsia Pharmaceuticals; has been involved in a patent application with Yale University and Novartis; has received research support from Mohegan Sun Casino and the Connecticut Council on Problem Gambling; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse-control disorders or other health topics; has consulted for and/or advised gambling and legal entities on issues related to impulsive, compulsive and addictive disorders; has edited journals and journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. Dr Coloma and Dr Steiner are full-time employees of, and own shares at, Idorsia Pharmaceuticals Ltd. Dr Malik and Dr Dawson are full-time employees of P1vital Ltd. Dr Beckenstrom and Dr Finlayson are part-time employees of P1vital Ltd. The other authors do not report disclosures., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Predictive validity in drug discovery: what it is, why it matters and how to improve it.
- Author
-
Scannell JW, Bosley J, Hickman JA, Dawson GR, Truebel H, Ferreira GS, Richards D, and Treherne JM
- Subjects
- Humans, Drug Discovery methods, Efficiency
- Abstract
Successful drug discovery is like finding oases of safety and efficacy in chemical and biological deserts. Screens in disease models, and other decision tools used in drug research and development (R&D), point towards oases when they score therapeutic candidates in a way that correlates with clinical utility in humans. Otherwise, they probably lead in the wrong direction. This line of thought can be quantified by using decision theory, in which 'predictive validity' is the correlation coefficient between the output of a decision tool and clinical utility across therapeutic candidates. Analyses based on this approach reveal that the detectability of good candidates is extremely sensitive to predictive validity, because the deserts are big and oases small. Both history and decision theory suggest that predictive validity is under-managed in drug R&D, not least because it is so hard to measure before projects succeed or fail later in the process. This article explains the influence of predictive validity on R&D productivity and discusses methods to evaluate and improve it, with the aim of supporting the application of more effective decision tools and catalysing investment in their creation., (© 2022. Springer Nature Limited.)
- Published
- 2022
- Full Text
- View/download PDF
25. Theory of Mind and social functioning among neuropsychiatric disorders: A transdiagnostic study.
- Author
-
Braak S, Su T, Krudop W, Pijnenburg YAL, Reus LM, van der Wee N, Bilderbeck AC, Dawson GR, van Rossum IW, Campos AV, Arango C, Saris IMJ, Kas MJ, and Penninx BWJH
- Abstract
Social dysfunction is commonly present in neuropsychiatric disorders of schizophrenia (SZ) and Alzheimer's disease (AD). Theory of Mind (ToM) deficits have been linked to social dysfunction in disease-specific studies. Nevertheless, it remains unclear how ToM is related to social functioning across these disorders, and which factors contribute to this relationship. We investigated transdiagnostic associations between ToM and social functioning among SZ/AD patients and healthy controls, and explored to what extent these associations relate to information processing speed or facial emotion recognition capacity. A total of 163 participants were included (SZ: n=56, AD: n=50 and age-matched controls: n=57). Social functioning was assessed with the Social Functioning Scale (SFS) and the De Jong-Gierveld Loneliness Scale (LON). ToM was measured with the Hinting Task. Information processing speed was measured by the Digit Symbol Substitution Test (DSST) and facial emotion recognition capacity by the facial emotion recognition task (FERT). Case-control deficits in Hinting Task performance were larger in AD (r
rb = -0.57) compared to SZ (rrb = -0.35). Poorer Hinting Task performance was transdiagnostically associated with the SFS (βHinting-Task = 1.20, p<0.01) and LON (βHinting-Task = -0.27, p<0.05). DSST, but not FERT, reduced the association between the SFS and Hinting Task performance, however the association remained significant (βHinting-Task = 0.95, p<0.05). DSST and FERT performances did not change the association between LON and Hinting Task performance. Taken together, ToM deficits are transdiagnostically associated with social dysfunction and this is partly related to reduced information processing speed., Competing Interests: Conflicts of Interest G.R. Dawson is co-owner and employee of P1vital LTD who provide the FERT and the digital version of the DSST for this study. A. Bilderbeck is an employee of P1vital LTD who provide the FERT and the digital version of the DSST for this study. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr van der Wee was on advisory boards for Pfizer, Servier and Eli Lilly and received grants from the EU and the Netherlands Organisation for Health Research and Development. All other authors declare that they have no conflicts of interest., (Copyright © 2022. Published by Elsevier B.V.)- Published
- 2022
- Full Text
- View/download PDF
26. Feasibility, acceptability and costs of nurse-led Alpha-Stim cranial electrostimulation to treat anxiety and depression in university students.
- Author
-
Royal S, Keeling S, Kelsall N, Price L, Fordham R, Xydopoulos G, Dawson GR, Kingslake J, and Morriss R
- Subjects
- Adult, Anxiety therapy, Feasibility Studies, Female, Humans, Male, Nurse's Role, Students psychology, Universities, Young Adult, Depression therapy, Electric Stimulation Therapy
- Abstract
Background: Only a relatively low proportion of university students seek help for anxiety and depression disorders, partly because they dislike current drug and psychological treatment options and would prefer home-based care. The aim of this study is to determine the feasibility, acceptability and cost utility of Alpha-Stim cranial electrostimulation (CES) delivered through a nurse led primary care clinic as a daily treatment for anxiety and depression symptoms by the student at home in contrast to usual primary care., Method: Feasibility and acceptability of a nurse led clinic offering Alpha-Stim CES in terms of the take up and completion of the six-week course of Alpha-Stim CES. Change in score on the GAD-7 and PHQ-9 as measures of anxiety and depression symptoms at baseline and at 8 weeks following a course of Alpha-Stim CES. Similar evaluation in a non-randomised control group attending a family doctor over the same period. Cost-utility analysis of the nurse led Alpha-Stim CES and family doctor pathways with participants failing to improve following further NICE Guideline clinical care (facilitated self-help and cognitive behaviour therapy)., Results: Of 47 students (mean age 22.1, years, 79% female opting for Alpha-Stim CES at the nurse-led clinic 46 (97.9%) completed a 6-week daily course. Forty-seven (47) students comprised a comparison group receiving usual family doctor care. Both Alpha-Stim CES and usual family doctor care were associated with large effect size reductions in GAD-7 and PHQ-9 scores from baseline to 8 weeks. There were no adverse effects and only one participant showed a clinically important deterioration in the Alpha-Stim group. In the cost utility analysis, Alpha-Stim CES was a cheaper option than usual family doctor care under all deterministic or probabilistic assumptions., Conclusion: Nurse delivered Alpha-Stim CES may be a feasible, acceptable and cheaper way of providing greater choice and home-based care for some university students seeking help from primary care with new presentations of anxiety and depression., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
27. Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer's disease patients.
- Author
-
Saris IMJ, Aghajani M, Jongs N, Reus LM, van der Wee NJA, Bilderbeck AC, Winter van Rossum I, Arango C, de la Torre-Luque A, Malik A, Raslescu A, Dawson GR, Ayuso-Mateos JL, Kas MJ, and Penninx BWJH
- Subjects
- Humans, Loneliness, Social Adjustment, Social Interaction, Alzheimer Disease, Schizophrenia diagnosis
- Abstract
Background: Social functioning is often impaired in schizophrenia (SZ) and Alzheimer's disease (AD). However, commonalities and differences in social dysfunction among these patient groups remain elusive., Materials and Methods: Using data from the PRISM study, behavioral (all subscales and total score of the Social Functioning Scale) and affective (perceived social disability and loneliness) indicators of social functioning were measured in patients with SZ (N = 56), probable AD (N = 50) and age-matched healthy controls groups (HC, N = 29 and N = 28). We examined to what extent social functioning differed between disease and age-matched HC groups, as well as between patient groups. Furthermore, we examined how severity of disease and mood were correlated with social functioning, irrespective of diagnosis., Results: As compared to HC, both behavioral and affective social functioning seemed impaired in SZ patients (Cohen's d's 0.81-1.69), whereas AD patients mainly showed impaired behavioral social function (Cohen's d's 0.65-1.14). While behavioral indices of social functioning were similar across patient groups, SZ patients reported more perceived social disability than AD patients (Cohen's d's 0.65). Across patient groups, positive mood, lower depression and anxiety levels were strong determinants of better social functioning (p's <0.001), even more so than severity of disease., Conclusions: AD and SZ patients both exhibit poor social functioning in comparison to age- and sex matched HC participants. Social dysfunction in SZ patients may be more severe than in AD patients, though this may be due to underreporting by AD patients. Across patients, social functioning appeared as more influenced by mood states than by severity of disease., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. ACB has received salaries from P1vital Ltd. MK has received (non-related) research funding from Novartis. BP has received (non-related) research funding from Jansen Research and Boehringer Ingelheim. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2022
- Full Text
- View/download PDF
28. Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders.
- Author
-
de la Torre-Luque A, Viera-Campos A, Bilderbeck AC, Carreras MT, Vivancos J, Diaz-Caneja CM, Aghajani M, Saris IMJ, Raslescu A, Malik A, Clark J, Penninx BWJH, van der Wee N, Rossum IW, Sommer B, Marston H, Dawson GR, Kas MJ, Ayuso-Mateos JL, and Arango C
- Subjects
- Adult, Anxiety, Cues, Female, Humans, Male, Self Report, Surveys and Questionnaires, Alzheimer Disease physiopathology, Facial Recognition, Schizophrenia physiopathology, Social Isolation
- Abstract
Background: Emotion recognition constitutes a pivotal process of social cognition. It involves decoding social cues (e.g., facial expressions) to maximise social adjustment. Current theoretical models posit the relationship between social withdrawal factors (social disengagement, lack of social interactions and loneliness) and emotion decoding., Objective: To investigate the role of social withdrawal in patients with schizophrenia (SZ) or probable Alzheimer's disease (AD), neuropsychiatric conditions associated with social dysfunction., Methods: A sample of 156 participants was recruited: schizophrenia patients (SZ; n = 53), Alzheimer's disease patients (AD; n = 46), and two age-matched control groups (SZc, n = 29; ADc, n = 28). All participants provided self-report measures of loneliness and social functioning, and completed a facial emotion detection task., Results: Neuropsychiatric patients (both groups) showed poorer performance in detecting both positive and negative emotions compared with their healthy counterparts (p < .01). Social withdrawal was associated with higher accuracy in negative emotion detection, across all groups. Additionally, neuropsychiatric patients with higher social withdrawal showed lower positive emotion misclassification., Conclusions: Our findings help to detail the similarities and differences in social function and facial emotion recognition in two disorders rarely studied in parallel, AD and SZ. Transdiagnostic patterns in these results suggest that social withdrawal is associated with heightened sensitivity to negative emotion expressions, potentially reflecting hypervigilance to social threat. Across the neuropsychiatric groups specifically, this hypervigilance associated with social withdrawal extended to positive emotion expressions, an emotional-cognitive bias that may impact social functioning in people with severe mental illness., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
29. Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer's disease.
- Author
-
Saris IMJ, Aghajani M, Reus LM, Visser PJ, Pijnenburg Y, van der Wee NJA, Bilderbeck AC, Raslescu A, Malik A, Mennes M, Koops S, Arrango C, Ayuso-Mateos JL, Dawson GR, Marston H, Kas MJ, and Penninx BWJH
- Subjects
- Humans, Neural Pathways diagnostic imaging, Default Mode Network, Magnetic Resonance Imaging, Brain diagnostic imaging, Brain Mapping, Nerve Net diagnostic imaging, Schizophrenia diagnostic imaging, Alzheimer Disease diagnostic imaging
- Abstract
Objectives: Social dysfunction is one of the most common signs of major neuropsychiatric disorders. The Default Mode Network (DMN) is crucially implicated in both psychopathology and social dysfunction, although the transdiagnostic properties of social dysfunction remains unknown. As part of the pan-European PRISM (Psychiatric Ratings using Intermediate Stratified Markers) project, we explored cross-disorder impact of social dysfunction on DMN connectivity., Methods: We studied DMN intrinsic functional connectivity in relation to social dysfunction by applying Independent Component Analysis and Dual Regression on resting-state fMRI data, among schizophrenia (SZ; N = 48), Alzheimer disease (AD; N = 47) patients and healthy controls (HC; N = 55). Social dysfunction was operationalised via the Social Functioning Scale (SFS) and De Jong-Gierveld Loneliness Scale (LON)., Results: Both SFS and LON were independently associated with diminished DMN connectional integrity within rostromedial prefrontal DMN subterritories ( p
corrected range = 0.02-0.04). The combined effect of these indicators (Mean.SFS + LON) on diminished DMN connectivity was even more pronounced (both spatially and statistically), independent of diagnostic status, and not confounded by key clinical or sociodemographic effects, comprising large sections of rostromedial and dorsomedial prefrontal cortex ( pcorrected =0.01)., Conclusions: These findings pinpoint DMN connectional alterations as putative transdiagnostic endophenotypes for social dysfunction and could aid personalised care initiatives grounded in social behaviour.- Published
- 2022
- Full Text
- View/download PDF
30. Validation of the P1vital® Faces Set for Use as Stimuli in Tests of Facial Emotion Recognition.
- Author
-
Romano JA, Vosper L, Kingslake JA, Dourish CT, Higgs S, Thomas JM, Raslescu A, and Dawson GR
- Abstract
Background: Negative bias in facial emotion recognition is a well-established concept in mental disorders such as depression. However, existing face sets of emotion recognition tests may be of limited use in international research, which could benefit from more contemporary and diverse alternatives. Here, we developed and provide initial validation for the P1vital® Affective Faces set (PAFs) as a contemporary alternative to the widely-used Pictures of Facial Affect (PoFA)., Methods: The PAFs was constructed of 133 color photographs of facial expressions of ethnically-diverse trained actors and compared with the PoFA, comprised of 110 black and white photographs of facial expressions of generally Caucasian actors. Sixty-one recruits were asked to classify faces from both sets over six emotions (happy, sad, fear, anger, disgust, surprise) varying in intensity in 10% increments from 0 to 100%., Results: Participants were significantly more accurate in identifying correct emotions viewing faces from the PAFs. In both sets, participants identified happy faces more accurately than fearful faces, were least likely to misclassify facial expressions as happy and most likely to misclassify all emotions at low intensity as neutral. Accuracy in identifying facial expressions improved with increasing emotion intensity for both sets, reaching peaks at 60 and 80% intensity for the PAFs and PoFA, respectively. The study was limited by small sizes and age-range of participants and ethnic diversity of actors., Conclusions: The PAFs successfully depicted a range of emotional expressions with improved performance over the PoFA and may be used as a contemporary set in facial expression recognition tests., Competing Interests: GD was a full-time employee of P1vital Ltd. AR, JR, CD, and LV were employed by P1vital Ltd. at the time this research was conducted. JK was a full-time employee of P1vital Products Ltd. The P1vital Affective Faces are the property of P1vital Products Ltd. GD and CD are co-owners and major shareholders of P1vital Ltd. GD, JK, and CD are major shareholders in P1vital Products Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Romano, Vosper, Kingslake, Dourish, Higgs, Thomas, Raslescu and Dawson.)
- Published
- 2022
- Full Text
- View/download PDF
31. Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients.
- Author
-
Jongs N, Penninx B, Arango C, Ayuso-Mateos JL, van der Wee N, Rossum IW, Saris IMJ, van Echteld A, Koops S, Bilderbeck AC, Raslescu A, Dawson GR, Sommer B, Marston H, Vorstman JA, Eijkemans MJ, and Kas MJ
- Subjects
- Bias, Caregivers psychology, Humans, Social Interaction, Alzheimer Disease complications, Alzheimer Disease psychology, Schizophrenia complications
- Abstract
Background: Questionnaires are the current hallmark for quantifying social functioning in human clinical research. In this study, we compared self- and proxy-rated (caregiver and researcher) assessments of social functioning in Schizophrenia (SZ) and Alzheimer's disease (AD) patients and evaluated if the discrepancy between the two assessments is mediated by disease-related factors such as symptom severity., Methods: We selected five items from the WHO Disability Assessment Schedule 2.0 (WHODAS) to assess social functioning in 53 AD and 61 SZ patients. Caregiver- and researcher-rated assessments of social functioning were used to calculate the discrepancies between self-rated and proxy-rated assessments. Furthermore, we used the number of communication events via smartphones to compare the questionnaire outcomes with an objective measure of social behaviour., Results: WHODAS results revealed that both AD (p < 0.001) and SZ (p < 0.004) patients significantly overestimate their social functioning relative to the assessment of their caregivers and/or researchers. This overestimation is mediated by the severity of cognitive impairments (MMSE; p = 0.019) in AD, and negative symptoms (PANSS; p = 0.028) in SZ. Subsequently, we showed that the proxy scores correlated more strongly with the smartphone communication events of the patient when compared to the patient-rated questionnaire scores (self; p = 0.076, caregiver; p < 0.001, researcher-rated; p = 0.046)., Conclusion: Here we show that the observed overestimation of WHODAS social functioning scores in AD and SZ patients is partly driven by disease-related biases such as cognitive impairments and negative symptoms, respectively. Therefore, we postulate the development and implementation of objective measures of social functioning that may be less susceptible to such biases., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
32. Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment.
- Author
-
Dawson GR, Post A, Smart TS, Browning M, and Harmer CJ
- Subjects
- Adult, Biomarkers, Double-Blind Method, Female, Humans, Male, Middle Aged, Narcotic Antagonists administration & dosage, Outcome Assessment, Health Care, Pyrans administration & dosage, Spiro Compounds administration & dosage, Nociceptin Receptor, Depressive Disorder, Major drug therapy, Emotions drug effects, Facial Expression, Facial Recognition drug effects, Narcotic Antagonists pharmacology, Pyrans pharmacology, Receptors, Opioid drug effects, Spiro Compounds pharmacology
- Abstract
Background: Clinical trials with putative antidepressants can be difficult to execute as it can take up to 8 weeks before differences emerge between drug and placebo, and long expensive trials often fail. Implementation of early response biomarkers could aid this process significantly with potential to identify new treatments., Aims: In a secondary analysis, we examined the association of early effects on emotional processing with later clinical outcome following treatment with the novel NOP antagonist LY2940094 versus placebo. We hypothesised that early induction of positive bias would be associated with reduced severity of depression after 8 weeks of treatment., Methods: This was a multicentre, randomised, double-blind, parallel-group, fixed-dose, placebo-controlled, 8 week study to assess sensitivity of the facial emotional recognition task (FERT) to early changes in emotional bias induced by LY2940094. Patients who met diagnostic criteria for major depression were randomised to receive LY2940094 ( N = 70) or placebo ( N = 66). At week 1 and 6, the FERT was completed by 33 patients in the LY2940094 group and 34 in the placebo group., Results: Patients identified happy faces with higher accuracy (Wald χ
2 (1,33) = 14.25, p < 0.001) after 1 week treatment with LY290094 compared to placebo (Wald χ2 (1,32) = 0.83, p = 0.36) and this correlated with eventual treatment response measured by the Hamilton Depression Rating Scale 7 weeks later., Conclusion: These data suggest that emotional processing biomarkers may be sensitive to early effects of antidepressant treatment indicative of later clinical response. Further studies in this area may be useful in developing new treatments and clinical trial designs for predicting antidepressant response.- Published
- 2021
- Full Text
- View/download PDF
33. From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
- Author
-
Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, and Tobin AB
- Subjects
- Aged, Aged, 80 and over, Aging pathology, Alzheimer Disease complications, Alzheimer Disease diagnostic imaging, Alzheimer Disease pathology, Amino Acid Sequence, Animals, Blood Pressure drug effects, CHO Cells, Cholinesterase Inhibitors pharmacology, Cricetulus, Crystallization, Disease Models, Animal, Dogs, Donepezil pharmacology, Electroencephalography, Female, HEK293 Cells, Heart Rate drug effects, Humans, Male, Mice, Inbred C57BL, Models, Molecular, Molecular Dynamics Simulation, Nerve Degeneration complications, Nerve Degeneration pathology, Primates, Rats, Receptor, Muscarinic M1 chemistry, Signal Transduction, Structural Homology, Protein, Mice, Alzheimer Disease drug therapy, Drug Design, Receptor, Muscarinic M1 agonists
- Abstract
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects. Here we aimed to design the drug properties needed for a well-tolerated M1-agonist with the potential to alleviate cognitive loss by taking a stepwise translational approach from atomic structure, cell/tissue-based assays, evaluation in preclinical species, clinical safety testing, and finally establishing activity in memory centers in humans. Through this approach, we rationally designed the optimal properties, including selectivity and partial agonism, into HTL9936-a potential candidate for the treatment of memory loss in Alzheimer's disease. More broadly, this demonstrates a strategy for targeting difficult GPCR targets from structure to clinic., Competing Interests: Declaration of interests T.T. and M.W. are shareholders and board members of Sosei Heptares. The authors A.J.H.B., G.A.B., K.A.B., J.B., J.E.C., M.S.C., R.M.C., J.C.E., E.H., A.J., C.J.L., J.L., F.H.M., P.J.N., K.O., G.O., J.C.P., M.P., N.R., P.R., B.G.T., R.T.S., C.d.G., G.M., and B.T. are or have been employees of Heptares Therapeutics and are shareholders of Sosei Heptares., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
34. The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial.
- Author
-
Browning M, Bilderbeck AC, Dias R, Dourish CT, Kingslake J, Deckert J, Goodwin GM, Gorwood P, Guo B, Harmer CJ, Morriss R, Reif A, Ruhe HG, van Schaik A, Simon J, Sola VP, Veltman DJ, Elices M, Lever AG, Menke A, Scanferla E, Stäblein M, and Dawson GR
- Subjects
- Algorithms, Anxiety Disorders drug therapy, Humans, Treatment Outcome, Antidepressive Agents therapeutic use, Primary Health Care
- Abstract
Depressed patients often do not respond to the first antidepressant prescribed, resulting in sequential trials of different medications. Personalised medicine offers a means of reducing this delay; however, the clinical effectiveness of personalised approaches to antidepressant treatment has not previously been tested. We assessed the clinical effectiveness of using a predictive algorithm, based on behavioural tests of affective cognition and subjective symptoms, to guide antidepressant treatment. We conducted a multicentre, open-label, randomised controlled trial in 913 medication-free depressed patients. Patients were randomly assigned to have their antidepressant treatment guided by a predictive algorithm or treatment as usual (TaU). The primary outcome was the response of depression symptoms, defined as a 50% or greater reduction in baseline score of the QIDS-SR-16 scale, at week 8. Additional prespecified outcomes included symptoms of anxiety at week 8, and symptoms of depression and functional outcome at weeks 8, 24 and 48. The response rate of depressive symptoms at week 8 in the PReDicT (55.9%) and TaU (51.8%) arms did not differ significantly (odds ratio: 1.18 (95% CI: 0.89-1.56), P = 0.25). However, there was a significantly greater reduction of anxiety in week 8 and a greater improvement in functional outcome at week 24 in the PReDicT arm. Use of the PReDicT test did not increase the rate of response to antidepressant treatment estimated by depressive symptoms but did improve symptoms of anxiety at week 8 and functional outcome at week 24. Our findings indicate that personalisation of antidepressant treatment may improve outcomes in depressed patients.
- Published
- 2021
- Full Text
- View/download PDF
35. Optimizing Behavioral Paradigms to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder: Study Protocol.
- Author
-
Bilderbeck AC, Raslescu A, Hernaus D, Hayen A, Umbricht D, Pemberton D, Tiller J, Søgaard B, Sambeth A, van Amelsvoort T, Reif A, Papazisis G, Pérez V, Elices M, Maurice D, Bertaina-Anglade V, Dawson GR, and Pollentier S
- Abstract
Background: Behavioral tasks focusing on different subdomains of reward processing may provide more objective and quantifiable measures of anhedonia and impaired motivation compared with clinical scales. Typically, single tasks are used in relatively small studies to compare cases and controls in one indication, but they are rarely included in larger multisite trials. This is due to limited systematic standardization as well as the challenges of deployment in international studies and stringent adherence to the high regulatory requirements for data integrity. The Reward Task Optimization Consortium (RTOC) was formed to facilitate operational implementation of reward processing tasks, making them suitable for use in future large-scale, international, multisite drug development studies across multiple indications. The RTOC clinical study aims to conduct initial optimization of a set of tasks in patients with major depressive disorder (MDD) or schizophrenia (SZ). Methods: We will conduct a multicenter study across four EU countries. Participants (MDD = 37, SZ = 37, with ≤80 age- and gender-matched healthy volunteers) will attend a study visit comprising screening, self-report and clinically rated assessments of anhedonia and symptom severity, and three reward processing tasks; specifically, the Grip Strength Effort task, the Doors task, and the Reinforcement Learning Working Memory task. The Grip Strength Effort and Doors tasks include simultaneous electroencephalography/event-related potential recordings. Outcomes will be compared using a two-way group design of MDD and SZ with matched controls, respectively. Further analyses will include anhedonia assessment scores as covariates. Planned analyses will assess whether our findings replicate previously published data, and multisite deployment will be evaluated through assessments of quality and conduct. A subset of participants will complete a second visit, to assess test-retest reliability of the task battery. Discussion: This study will evaluate the operational deployment of three reward processing tasks to the regulatory standards required for use in drug development trials. We will explore the potential of these tasks to differentiate patients from controls and to provide a quantitative marker of anhedonia and/or impaired motivation, establishing their usefulness as endpoints in multisite clinical trials. This study should demonstrate where multifaceted reward deficits are similar or divergent across patient populations. Registration : ClinicalTrials.gov (NCT04024371)., (Copyright © 2020 Bilderbeck, Raslescu, Hernaus, Hayen, Umbricht, Pemberton, Tiller, Søgaard, Sambeth, van Amelsvoort, Reif, Papazisis, Pérez, Elices, Maurice, Bertaina-Anglade, Dawson and Pollentier.)
- Published
- 2020
- Full Text
- View/download PDF
36. Value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: a modelling study.
- Author
-
Simon J, Harmer CJ, Kingslake J, Dawson GR, Dourish CT, and Goodwin GM
- Subjects
- Clinical Decision-Making, England, Evidence-Based Medicine, Humans, Antidepressive Agents economics, Antidepressive Agents pharmacology, Cost-Benefit Analysis, Depressive Disorder drug therapy, Depressive Disorder economics, Monitoring, Physiologic economics, Outcome Assessment, Health Care economics, Primary Health Care economics, Quality-Adjusted Life Years
- Abstract
Background: Depressed patients often focus on negative life events. Effective antidepressant therapy reverses this negative emotional bias (NEB) within 1 week. Clinical therapeutic effect usually requires 4-6 weeks. The value of implementing NEB monitoring for the personalisation of antidepressant therapy is unknown., Objective: To estimate the likely outcome and cost consequences of adopting the P1vital Oxford Emotional Test Battery (ETB) for this purpose in routine primary care in England., Methods: A hybrid decision analytic model (decision tree plus Markov model) was developed to estimate the cost-effectiveness of ETB monitoring versus no ETB over 52 weeks using quality-adjusted life years (QALYs). Differences in depression severity, episode type and analytical perspectives were considered. Input data were derived from relevant guidelines, literature, national databases, expert opinion and the developers for the year 2013. Multiple sensitivity analyses addressed uncertainty., Findings: The mean number of ETB tests is 2.162 per newly diagnosed patient and 2.166 per patient with recurrent depression. The incremental cost-effectiveness of ETB versus 'no ETB' is £4355/QALY from the healthcare perspective. From the broader societal perspective, ETB is more effective and cost saving., Conclusions: Monitoring negative emotional bias in primary care in England for personalised antidepressant treatment using ETB seems as an effective and cost-effective option under all considered scenarios (including worst case). Its main economic value seems to lie in reduced productivity loss as opposed to healthcare savings., Clinical Implications: The test supports accelerated application of evidence-based depression care. Further optimisation and implementation in the ongoing European PReDicT trial is ongoing., Competing Interests: Competing interests: GRD, JK and CTD own shares in P1vital Products Ltd. JK is an employee of P1vital Products Ltd. GRD, CTD, GMG and CJH own shares in P1vital Ltd. GRD and CTD are employees of P1vital Ltd., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
37. Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease.
- Author
-
Bilderbeck AC, Penninx BWJH, Arango C, van der Wee N, Kahn R, Winter-van Rossum I, Hayen A, Kas MJ, Post A, and Dawson GR
- Subjects
- Alzheimer Disease physiopathology, Biomarkers blood, Brain Mapping, Electroencephalography, Epigenesis, Genetic, Humans, Magnetic Resonance Imaging, Psychiatric Status Rating Scales, Research Design, Schizophrenia physiopathology, Alzheimer Disease diagnosis, Alzheimer Disease psychology, Brain physiopathology, Cognition, Schizophrenia diagnosis, Schizophrenic Psychology, Social Isolation
- Abstract
Trans-diagnostic, domain- or symptom-focused approaches have been heralded as advancing psychiatric research, but relatively few clinical research programmes have been undertaken to leverage their potential. In this manuscript we describe the approach and protocol for an exploratory study, PRISM (Psychiatric Ratings using Intermediate Stratified Markers), that will be conducted to explore the biomarkers in schizophrenia (SZ) and Alzheimer's Disease (AD) that may be related to a common symptom, social withdrawal. Patient participants (N = 72 SZ and N = 72 AD study completers), will complete a series of fMRI, EEG, and behavioural paradigms, as well as contributing blood-derived (e.g. epigenetic) and smartphone data related to social behaviour. Self- as well as caregiver- and researcher-reported assessments will be provided to characterise social withdrawal. Normative data will also be collected from a group of healthy controls (N = 48 study completers), half of whom will be matched in terms of age and gender distribution to the SZ and AD group, respectively. Thus we will explore both differentiation and cross-diagnostic overlap in the biomarkers associated with different levels of social withdrawal in SZ and AD. In this way we aim to provide a deeper understanding of the biological underpinnings of symptomatology common to both disorders, and provide insights into novel treatment targets and future drug development approaches., (Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
38. Predicting treatment response to antidepressant medication using early changes in emotional processing.
- Author
-
Browning M, Kingslake J, Dourish CT, Goodwin GM, Harmer CJ, and Dawson GR
- Subjects
- Adolescent, Adult, Aged, Algorithms, Depression diagnosis, Diagnosis, Computer-Assisted methods, Facial Expression, Female, Humans, Male, Middle Aged, Primary Health Care methods, Recognition, Psychology, Time Factors, Treatment Outcome, Young Adult, Antidepressive Agents therapeutic use, Citalopram therapeutic use, Depression drug therapy, Depression psychology, Emotions drug effects, Forecasting methods
- Abstract
Antidepressants must be taken for weeks before response can be assessed with many patients not responding to the first medication prescribed. This often results in long delays before effective treatment is started. Antidepressants induce changes in the processing of emotional stimuli early in the course of treatment. In the current study we assessed whether changes in emotional processing and subjective symptoms over the first week of antidepressant treatment predicted clinical response after 4-8 weeks of treatment. Such a predictive test may shorten the time taken to initiate effective treatment in depressed patients. Seventy-four depressed primary care patients completed measures of emotional bias and subjective symptoms before starting antidepressant treatment and then again 1 week later. Response to treatment was assessed after 4-6 weeks. The performance of classifiers based on these measures was assessed using a leave-one-out validation procedure with the best classifier then tested in an independent sample from a second study of 239 patients. The combination of a facial emotion recognition task and subjective symptoms predicted response with 77% accuracy in the training sample and 60% accuracy in the independent study, significantly better than possible using baseline response rates. The face based measure of emotional bias provided good quality data with high acceptability ratings. Changes in emotional processing can provide a sensitive early measure of antidepressant efficacy for individual patients. Early treatment induced changes in emotional processing may be used to guide antidepressant therapy and reduce the time taken for depressed patients to return to good mental health., (Copyright © 2018. Published by Elsevier B.V.)
- Published
- 2019
- Full Text
- View/download PDF
39. Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA A Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.
- Author
-
Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, Tiruveedhula VVNPB, Li G, Stephen MR, Sieghart W, Cook JM, and Rowlett JK
- Subjects
- Animals, Behavior, Animal drug effects, Female, Macaca mulatta, Male, Benzodiazepines pharmacology, Hypnotics and Sedatives pharmacology, Receptors, GABA-A metabolism
- Abstract
In nonhuman primates we tested a new set of behavioral categories for observable sedative effects using pediatric anesthesiology classifications as a basis. Using quantitative behavioral observation techniques in rhesus monkeys, we examined the effects of alprazolam and diazepam (nonselective benzodiazepines), zolpidem (preferential binding to α 1 subunit-containing GABA
A receptors), HZ-166 (8-ethynyl-6-(2'-pyridine)-4 H -2,5,10b-triaza-benzo[ e ]azulene-3-carboxylic acid ethyl ester; functionally selective with relatively high intrinsic efficacy for α 2 and α 3 subunit-containing GABAA receptors), MRK-696 [7-cyclobutyl-6-(2-methyl-2 H -1,2,4-triazol-2-ylmethoxy)-3-(2-flurophenyl)-1,2,4-triazolo(4,3- b )pyridazine; no selectivity but partial intrinsic activity], and TPA023B 6,2'-diflouro-5'-[3-(1-hydroxy-1-methylethyl)imidazo[1,2- b ][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile; partial intrinsic efficacy and selectivity for α 2, α 3, α 5 subunit-containing GABAA receptors]. We further examined the role of α 1 subunit-containing GABAA receptors in benzodiazepine-induced sedative effects by pretreating animals with the α 1 subunit-preferring antagonist β -carboline-3-carboxylate- t -butyl ester ( β CCT). Increasing doses of alprazolam and diazepam resulted in the emergence of observable ataxia, rest/sleep posture, and moderate and deep sedation. In contrast, zolpidem engendered dose-dependent observable ataxia and deep sedation but not rest/sleep posture or moderate sedation, and HZ-166 and TPA023 induced primarily rest/sleep posture. MRK-696 induced rest/sleep posture and observable ataxia. Zolpidem, but no other compounds, significantly increased tactile/oral exploration. The sedative effects engendered by alprazolam, diazepam, and zolpidem generally were attenuated by β CCT pretreatments, whereas rest/sleep posture and suppression of tactile/oral exploration were insensitive to β CCT administration. These data suggest that α 2/3-containing GABAA receptor subtypes unexpectedly may mediate a mild form of sedation (rest/sleep posture), whereas α 1-containing GABAA receptors may play a role in moderate/deep sedation., (Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.)- Published
- 2018
- Full Text
- View/download PDF
40. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
- Author
-
Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, Olsen CK, Christensen SR, Dawson GR, Deakin JF, Hawkins P, Morris R, Goodwin G, and Harmer CJ
- Subjects
- Adult, Affect drug effects, Antidepressive Agents pharmacology, Cognition Disorders drug therapy, Cognitive Dysfunction drug therapy, Depression drug therapy, Depressive Disorder, Major drug therapy, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging methods, Male, Middle Aged, Neuroimaging, Neuropsychological Tests, Treatment Outcome, Vortioxetine therapeutic use, Cognition drug effects, Memory, Short-Term drug effects, Vortioxetine pharmacology
- Abstract
Cognitive dysfunction is common in depression during both acute episodes and remission. Vortioxetine is a novel multimodal antidepressant that has improved cognitive function including executive function in depressed patients in randomised placebo-controlled clinical trials. However, it is unclear whether vortioxetine is able to target directly the neural circuitry implicated in the cognitive deficits in depression. Remitted depressed (n=48) and healthy volunteers (n=48) were randomised to receive 14 days treatment with 20 mg vortioxetine or placebo in a double-blind design. The effects of treatment on functional magnetic resonance imaging responses during an N-back working memory task were assessed at baseline and at the end of treatment. Neuropsychological measures of executive function, speed and information processing, attention and learning and memory were examined with the Trail Making Test (TMT), Rey Auditory Learning Test and Digit Symbol Substitution Test before and after treatment; subjective cognitive function was assessed using the Perceived Deficits Questionnaire (PDQ). Compared with placebo, vortioxetine reduced activation in the right dorsolateral prefrontal cortex and left hippocampus during the N-back task compared with placebo. Vortioxetine also increased TMT-A performance and self-reported cognitive function on the PDQ. These effects were seen across both subject groups. Vortioxetine modulates neural responses across a circuit subserving working memory in a direction opposite to the changes described in depression, when performance is maintained. This study provides evidence that vortioxetine has direct effects on the neural circuitry supporting cognitive function that can be dissociated from its effects on the mood symptoms of depression.
- Published
- 2018
- Full Text
- View/download PDF
41. The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial.
- Author
-
Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, Morriss R, Brown S, Guo B, Dourish CT, Ruhé HG, Lever AG, Veltman DJ, van Schaik A, Deckert J, Reif A, Stäblein M, Menke A, Gorwood P, Voegeli G, Pérez V, and Browning M
- Subjects
- Adolescent, Adult, Aged, Antidepressive Agents adverse effects, Clinical Decision-Making, Clinical Protocols, Cost-Benefit Analysis, Depression diagnosis, Depression economics, Depression psychology, Europe, Female, Health Care Costs, Humans, Male, Middle Aged, Patient Selection, Predictive Value of Tests, Research Design, Risk Factors, Surveys and Questionnaires, Time Factors, Time-to-Treatment, Treatment Outcome, Young Adult, Affect drug effects, Antidepressive Agents therapeutic use, Cognition drug effects, Decision Support Techniques, Depression drug therapy, Primary Health Care economics
- Abstract
Background: Antidepressant medication is commonly used to treat depression. However, many patients do not respond to the first medication prescribed and improvements in symptoms are generally only detectable by clinicians 4-6 weeks after the medication has been initiated. As a result, there is often a long delay between the decision to initiate an antidepressant medication and the identification of an effective treatment regimen. Previous work has demonstrated that antidepressant medications alter subtle measures of affective cognition in depressed patients, such as the appraisal of facial expression. Furthermore, these cognitive effects of antidepressants are apparent early in the course of treatment and can also predict later clinical response. This trial will assess whether an electronic test of affective cognition and symptoms (the Predicting Response to Depression Treatment Test; PReDicT Test) can be used to guide antidepressant treatment in depressed patients and, therefore, hasten treatment response compared to a control group of patients treated as usual., Methods/design: The study is a randomised, two-arm, multi-centre, open-label, clinical investigation of a medical device, the PReDicT Test. It will be conducted in five European countries (UK, France, Spain, Germany and the Netherlands) in depressed patients who are commencing antidepressant medication. Patients will be randomised to treatment guided by the PReDicT Test (PReDicT arm) or to Treatment as Usual (TaU arm). Patients in the TaU arm will be treated as per current standard guidelines in their particular country. Patients in the PReDicT arm will complete the PReDicT Test after 1 (and if necessary, 2) weeks of treatment. If the test indicates non-response to the treatment, physicians will be advised to immediately alter the patient's antidepressant therapy by dose escalation or switching to another compound. The primary outcome of the study is the proportion of patients showing a clinical response (defined as 50% or greater decrease in baseline scores of depression measured using the Quick Inventory of Depressive Symptoms - Self-Rated questionnaire) at week 8. Health economic and acceptability data will also be collected and analysed., Discussion: This trial will test the clinical efficacy, cost-effectiveness and acceptability of using the novel PReDicT Test to guide antidepressant treatment selection in depressed patients., Trial Registration: ClinicalTrials.gov, ID: NCT02790970 . Registered on 30 March 2016.
- Published
- 2017
- Full Text
- View/download PDF
42. Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
- Author
-
Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, and Witkin JM
- Abstract
[This corrects the article DOI: 10.1038/npp.2015.348.].
- Published
- 2016
- Full Text
- View/download PDF
43. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
- Author
-
Downey D, Dutta A, McKie S, Dawson GR, Dourish CT, Craig K, Smith MA, McCarthy DJ, Harmer CJ, Goodwin GM, Williams S, and Deakin JF
- Subjects
- Adolescent, Adult, Affect, Antidepressive Agents administration & dosage, Antidepressive Agents adverse effects, Cross-Over Studies, Depressive Disorder, Major diagnostic imaging, Double-Blind Method, Excitatory Amino Acid Antagonists administration & dosage, Excitatory Amino Acid Antagonists adverse effects, Female, Humans, Ketamine administration & dosage, Ketamine adverse effects, Magnetic Resonance Imaging, Male, Middle Aged, Phenethylamines administration & dosage, Phenethylamines adverse effects, Psychiatric Status Rating Scales, Pyridines administration & dosage, Pyridines adverse effects, Treatment Outcome, Young Adult, Antidepressive Agents therapeutic use, Depressive Disorder, Major drug therapy, Excitatory Amino Acid Antagonists therapeutic use, Gyrus Cinguli drug effects, Ketamine therapeutic use, Phenethylamines therapeutic use, Pyridines therapeutic use
- Abstract
Intravenous infusion of lanicemine (formerly AZD6765), a low trapping non-selective N-methyl-D-aspartate (NMDA) receptor antagonist, induces antidepressant effects with a similar time course to ketamine. We investigated whether a single dose lanicemine infusion would reproduce the previously reported decrease in subgenual anterior cingulate cortex (sgACC) activity evoked by ketamine, a potential mechanism of antidepressant efficacy. Sixty un-medicated adults meeting the criteria for major depressive disorder were randomly assigned to receive constant intravenous infusions of ketamine, lanicemine or saline during a 60min pharmacological magnetic resonance imaging (phMRI) scan. Both ketamine and lanicemine gradually increased the blood oxygen level dependent signal in sgACC and rostral ACC as the primary outcome measure. No decreases in signal were seen in any region. Interviewer-rated psychotic and dissociative symptoms were minimal following administration of lanicemine. There was no significant antidepressant effect of either infusion compared to saline. The previously reported deactivation of sgACC after ketamine probably reflects the rapid and pronounced subjective effects evoked by the bolus-infusion method used in the previous study. Activation of the ACC was observed following two different NMDA compounds in both Manchester and Oxford using different 3T MRI scanners, and this effect predicted improvement in mood 1 and 7 days post-infusion. These findings suggest that the initial site of antidepressant action for NMDA antagonists may be the ACC (NCT01046630. A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder; http://clinicaltrials.gov/show/NCT01046630)., (Copyright © 2016 Elsevier B.V. and ECNP. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
44. A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
- Author
-
Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, and Witkin JM
- Subjects
- Adolescent, Adult, Aged, Animals, Anti-Anxiety Agents pharmacology, Chlordiazepoxide pharmacology, Disease Models, Animal, Double-Blind Method, Eye Movements drug effects, Female, Follow-Up Studies, Humans, Male, Mice, Middle Aged, Prefrontal Cortex drug effects, Prefrontal Cortex metabolism, Pregnancy, Rats, Rats, Sprague-Dawley, Young Adult, Nociceptin Receptor, Depression drug therapy, Narcotic Antagonists therapeutic use, Pyrans therapeutic use, Receptors, Opioid metabolism, Spiro Compounds therapeutic use
- Abstract
Nociceptin/Orphanin FQ (N/OFQ) is an endogenous ligand of the N/OFQ peptide (NOP) receptor, which is a G protein-coupled receptor in brain regions associated with mood disorders. We used a novel, potent, and selective orally bioavailable antagonist, LY2940094, to test the hypothesis that blockade of NOP receptors would induce antidepressant effects. In this study we demonstrate that targeting NOP receptors with LY2940094 translates to antidepressant-like effects in rodent models and, importantly, to antidepressant efficacy in patients with major depressive disorder (MDD). The proof-of-concept study (POC) was an 8-week, double-blind, placebo-controlled trial that evaluated LY2940094 as a novel oral medication for the treatment of patients with MDD. Once daily oral dosing of LY2940094 at 40 mg for 8 weeks vs placebo provided some evidence for an antidepressant effect based on the change from baseline to week 8 in the GRID-Hamilton Depression Rating Scale-17 item total score, although the predefined POC efficacy criterion (probability of LY2940094 being better than placebo⩾88%) was not met (82.9%). LY2940094 also had an early effect on the processing of emotional stimuli at Week 1 as shown by an increased recognition of positive relative to negative facial expressions in an emotional test battery. LY2940094 was safe and well tolerated. Overall, these are the first human data providing evidence that the blockade of NOP receptor signaling represents a promising strategy for the treatment of MDD.
- Published
- 2016
- Full Text
- View/download PDF
45. Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies.
- Author
-
Koychev I, Joyce D, Barkus E, Ettinger U, Schmechtig A, Dourish CT, Dawson GR, Craig KJ, and Deakin JF
- Subjects
- Cognitive Dysfunction classification, Cognitive Dysfunction physiopathology, Cognitive Dysfunction psychology, Drug Discovery, Eye Movement Measurements, Female, Humans, Male, Schizophrenia classification, Schizophrenia physiopathology, Translational Research, Biomedical, Cognitive Dysfunction drug therapy, Nootropic Agents therapeutic use, Schizophrenia drug therapy, Schizophrenic Psychology
- Abstract
The development of drugs to improve cognition in patients with schizophrenia is a major unmet clinical need. A number of promising compounds failed in recent clinical trials, a pattern linked to poor translation between preclinical and clinical stages of drug development. Seeking proof of efficacy in early Phase 1 studies in surrogate patient populations (for example, high schizotypy individuals where subtle cognitive impairment is present) has been suggested as a strategy to reduce attrition in the later stages of drug development. However, there is little agreement regarding the pattern of distribution of schizotypal features in the general population, creating uncertainty regarding the optimal control group that should be included in prospective trials. We aimed to address this question by comparing the performance of groups derived from the general population with low, average and high schizotypy scores over a range of cognitive and oculomotor tasks. We found that tasks dependent on frontal inhibitory mechanisms (N-Back working memory and anti-saccade oculomotor tasks), as well as a smooth-pursuit oculomotor task were sensitive to differences in the schizotypy phenotype. In these tasks the cognitive performance of 'low schizotypes' was significantly different from 'high schizotypes' with 'average schizotypes' having an intermediate performance. These results indicate that for evaluating putative cognition enhancers for treating schizophrenia in early-drug development studies the maximum schizotypy effect would be achieved using a design that compares low and high schizotypes., Competing Interests: IK has been awarded a Manchester Strategic PhD Studentship, sponsored by the University of Manchester and P1vital Ltd. The PhD project of AS was partly funded by P1vital Ltd. UE is supported by the Deutsche Forschungsgemeinschaft (Et 31/2-1). JFWD has been supported by the Manchester Biomedical Research Centre. JFWD has carried out paid consultancy work and speaking engagements for Servier, Merck Sharpe and Dohme, Astrazeneca, Janssen, and Eli Lilly. The fees are paid to the University of Manchester to reimburse them for the time taken. JFWD, GRD and CTD own shares in P1vital Ltd. EB acknowledges the support of a Young Investigator Award from NARSAD. KJC worked for P1vital Ltd at the time that this research was conducted. He is currently an employee and shareholder in Covance Inc. DJ declares no relevant conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
46. Investigating virtual reality navigation in amnestic mild cognitive impairment using fMRI.
- Author
-
Migo EM, O'Daly O, Mitterschiffthaler M, Antonova E, Dawson GR, Dourish CT, Craig KJ, Simmons A, Wilcock GK, McCulloch E, Jackson SH, Kopelman MD, Williams SC, and Morris RG
- Subjects
- Aged, Aged, 80 and over, Brain Mapping, Female, Humans, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Amnesia physiopathology, Brain physiopathology, Cognitive Dysfunction physiopathology, Spatial Navigation physiology, User-Computer Interface
- Abstract
Spatial navigation requires a well-established network of brain regions, including the hippocampus, caudate nucleus, and retrosplenial cortex. Amnestic Mild Cognitive Impairment (aMCI) is a condition with predominantly memory impairment, conferring a high predictive risk factor for dementia. aMCI is associated with hippocampal atrophy and subtle deficits in spatial navigation. We present the first use of a functional Magnetic Resonance Imaging (fMRI) navigation task in aMCI, using a virtual reality analog of the Radial Arm Maze. Compared with controls, aMCI patients showed reduced activity in the hippocampus bilaterally, retrosplenial cortex, and left dorsolateral prefrontal cortex. Reduced activation in key areas for successful navigation, as well as additional regions, was found alongside relatively normal task performance. Results also revealed increased activity in the right dorsolateral prefrontal cortex in aMCI patients, which may reflect compensation for reduced activations elsewhere. These data support suggestions that fMRI spatial navigation tasks may be useful for staging of progression in MCI.
- Published
- 2016
- Full Text
- View/download PDF
47. Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition.
- Author
-
Dawson GR
- Subjects
- Animals, Biomedical Research, Cognition Disorders psychology, Depressive Disorder psychology, Disease Models, Animal, Humans, Schizophrenic Psychology, Cognition physiology, Cognition Disorders physiopathology, Depressive Disorder physiopathology, Schizophrenia physiopathology
- Abstract
The use of experimental medicine studies to bridge the gap between Phase 1 and 2 drug trials and so to enhance translation of basic neuroscience studies using experimental animals to the clinic is proposed. Illustrative examples are provided for affective disorders and schizophrenia in relation also to cognitive dysfunction.
- Published
- 2016
- Full Text
- View/download PDF
48. Alterations in working memory networks in amnestic mild cognitive impairment.
- Author
-
Migo EM, Mitterschiffthaler M, O'Daly O, Dawson GR, Dourish CT, Craig KJ, Simmons A, Wilcock GK, McCulloch E, Jackson SH, Kopelman MD, Williams SC, and Morris RG
- Subjects
- Aged, Analysis of Variance, Brain blood supply, Brain Mapping, Executive Function, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Neural Pathways blood supply, Neural Pathways pathology, Neuropsychological Tests, Oxygen blood, Psychomotor Performance, Reaction Time, Brain pathology, Cognitive Dysfunction complications, Cognitive Dysfunction pathology, Memory Disorders etiology, Memory, Short-Term physiology
- Abstract
Patients with amnestic mild cognitive impairment (aMCI) show preserved or mildly impaired working memory, despite their deficits in episodic memory. We aimed to identify performance and/or neural differences between aMCI patients and matched controls on a standard working memory fMRI task. Neuropsychological assessment demonstrated aMCI impairments in verbal and visual episodic long-term memory, with intact IQ and executive function. Participants completed a standard three-level N-back task where patients were unimpaired. Functional activations in the control group were found in expected areas, including the inferior parietal lobule and dorsolateral prefrontal cortex. Group differences were found in the insula and lingual gyrus and, in a region of interest analysis, in the hippocampus. In all cases, these were caused by an absence of task-related deactivations in the aMCI group. The results are consistent with reports of failure in task-related deacivations in aMCI and could be early indications of pathology.
- Published
- 2015
- Full Text
- View/download PDF
49. Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia.
- Author
-
Dourish CT and Dawson GR
- Subjects
- Antipsychotic Agents therapeutic use, Humans, Ketamine metabolism, Magnetic Resonance Imaging, Nicotine therapeutic use, Risperidone therapeutic use, Schizophrenia drug therapy, Schizophrenia pathology, Biomarkers metabolism, Schizophrenia metabolism
- Published
- 2014
- Full Text
- View/download PDF
50. The effects of ketamine and risperidone on eye movement control in healthy volunteers.
- Author
-
Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, William Deakin JF, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SC, and Ettinger U
- Subjects
- Adolescent, Adult, Antipsychotic Agents pharmacology, Double-Blind Method, Excitatory Amino Acid Antagonists pharmacology, Eye Movement Measurements, Eye Movements drug effects, Female, Healthy Volunteers, Humans, Ketamine pharmacology, Male, Ocular Motility Disorders chemically induced, Pursuit, Smooth drug effects, Risperidone pharmacology, Saccades drug effects, Schizophrenia, Young Adult, Antipsychotic Agents therapeutic use, Excitatory Amino Acid Antagonists adverse effects, Ketamine adverse effects, Ocular Motility Disorders drug therapy, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Risperidone therapeutic use
- Abstract
The non-competitive N-methyl-D-aspartate receptor antagonist ketamine leads to transient psychosis-like symptoms and impairments in oculomotor performance in healthy volunteers. This study examined whether the adverse effects of ketamine on oculomotor performance can be reversed by the atypical antipsychotic risperidone. In this randomized double-blind, placebo-controlled study, 72 healthy participants performed smooth pursuit eye movements (SPEM), prosaccades (PS) and antisaccades (AS) while being randomly assigned to one of four drug groups (intravenous 100 ng ml(-1) ketamine, 2 mg oral risperidone, 100 ng ml(-1) ketamine plus 2 mg oral risperidone, placebo). Drug administration did not lead to harmful adverse events. Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P < 0.01) but had no significant effects on PS or AS (all P > or = 0.07). An effect of risperidone was observed for amplitude gain and peak velocity of PS and AS, indicating hypometric gain and slower velocities compared with placebo (both P < or = 0.04). No ketamine by risperidone interactions were found (all P > or = 0.26). The results confirm that the administration of ketamine produces oculomotor performance deficits similar in part to those seen in schizophrenia. The atypical antipsychotic risperidone did not reverse ketamine-induced deteriorations. These findings do not support the cognitive enhancing potential of risperidone on oculomotor biomarkers in this model system of schizophrenia and point towards the importance of developing alternative performance-enhancing compounds to optimise pharmacological treatment of schizophrenia.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.